Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease

Core Insights - New data indicates that oral blarcamesine treatment leads to a significant time saving of 77.4 weeks (17.8 months) compared to the ADNI control group after 144 weeks (33.1 months) of treatment [1] - The presentation at the AD/PD™ 2026 Conference emphasizes the convenience of oral blarcamesine for patients and families [1] Group 1: Clinical Efficacy - Blarcamesine shows promising clinical efficacy, particularly in the genetically defined ABCLEAR3 population, which may experience greater benefits [2] - A dedicated analysis of MRI biomarkers reveals a strong correlation between the slowing of atrophy and improvements in clinical endpoints, with R² for ADAS-Cog13 increasing by 78% [3] Group 2: Company Overview - Anavex Life Sciences Corp. is focused on developing innovative treatments for neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease and Parkinson's disease [8] - Blarcamesine has completed Phase 2a and Phase 2b/3 clinical trials for Alzheimer's disease and has shown potential in treating other CNS disorders [8]